BridgeBio Pharma, Inc. BBIO
74.03 USD -0.97 (-1.29%)
At closeNov 3, 2026, 4:00 PM EST
74.03 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
73.95 Day range 76.79
60.22 52-week range 93.42
- YTD
- -3.22%
- 1 year
- +19.44%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 106.85 +44.3% upside
Now 74.03
- Target (low)
- 80.00
- Target (mean)
- 106.85
- Target (high)
- 156.00
Ratings (0m) 22 19 buy · 3 hold · 0 sell
- Strong buy5
- Buy14
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 22
- 1 month ago 22
- 2 months ago 22
- 3 months ago 22
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.48875 | -0.56 – -0.37 | -0.93893 | +47.9% | 303.05M | +96.6% | 4 |
| Next quarter | -0.30 | -0.52 – -0.18 | -0.84 | +64.3% | 336.46M | +73.0% | 3 |
| Current year | -2.37 | -2.60 – -2.09 | -3.78 | +37.4% | 1.10B | +118.4% | 4 |
| Next year | -0.32396 | -2.42 – 1.31 | -2.37 | +86.3% | 1.67B | +51.9% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 30, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 30, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 19, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Oct 19, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 1, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Aug 12, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 11, 2026 | B of A Securities | Maintained | Buy | Buy |
| Aug 11, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 11, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 11, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 11, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 16, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Jul 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 16, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jun 3, 2026 | Canaccord Genuity | Initiated | — | Buy |
| May 28, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 28, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 26, 2026 | Raymond James | Downgrade | Outperform | Market Perform |
| May 19, 2026 | Citigroup | Initiated | — | Neutral |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 8, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Apr 29, 2026 | Truist Securities | Maintained | Buy | Buy |
| Apr 29, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |